Clinical Trials Logo

Spondylitis, Ankylosing clinical trials

View clinical trials related to Spondylitis, Ankylosing.

Filter by:
  • Not yet recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06242652 Not yet recruiting - Clinical trials for Ankylosing Spondylitis

A Study to Evaluate 608 in Patients With Ankylosing Spondylitis (AS)

Start date: March 19, 2024
Phase: Phase 2
Study type: Interventional

This study will evaluate the effect and safety of 608 in patients with AS.

NCT ID: NCT06198985 Not yet recruiting - Clinical trials for Ankylosing Spondylitis

The Effect of Dynamic Balance Exercises on Balance in Patients With Ankylosing Spondylitis.

Start date: January 1, 2024
Phase: N/A
Study type: Interventional

The aim of the study is to investigate the effect of dynamic balance exercises added to current medical treatment on balance in patients with ankylosing spondylitis.

NCT ID: NCT06092775 Not yet recruiting - Vertebral Fracture Clinical Trials

Prevalence of Subclinical Vertebral Fractures in Rheumatoid Arthritis and Ankylosing Spondylitis

Start date: December 2023
Phase:
Study type: Observational

Study of prevalence of subclinical vertebral fractures in Rheumatoid Arthritis and Ankylosing spondylitis

NCT ID: NCT05962762 Not yet recruiting - Clinical trials for Ankylosing Spondylitis

Safety and Tolerance of Umbilical Cord Mesenchymal Stem Cells (UC-MSC) in Patients With Ankylosing Spondylitis

Start date: August 30, 2023
Phase: Phase 1
Study type: Interventional

The goal of this clinical trial is to evaluate the safety and tolerability of multiple doses of human umbilical cord mesenchymal stem cell injection in patients with Ankylosing Spondylitis, and to further explore the efficacy, pharmacodynamic profile and appropriate dose of administration to provide a basis for the use of safer and more effective treatments for patients with Ankylosing Spondylitis in the future. Participants are required to sign an informed consent form and, after undergoing a series of tests and meeting the protocol's entry and exclusion criteria, are assigned to a dose group for intravenous infusion of human umbilical cord mesenchymal stem cells.

NCT ID: NCT05960864 Not yet recruiting - Clinical trials for Ulcerative Colitis (UC)

Chinese Spondyloarthritis Inception Cohort (CESPIC)

CESPIC
Start date: September 2024
Phase:
Study type: Observational

The Chinese Spondyloarthritis Inception cohort (CESPIC) was started 2000 as a prospective, longitudinal, multicentre, nationwide study in China on patients with early SpA including ankylosing spondylitis (AS, also known as radiographic axial spondyloarthritis) and non-radiographic axial SpA. The objectives of CESPIC are to learn about the course of SpA during the very early stage of the disease, to appropriately assess the outcome including radiographic progression of patients after several years of follow-up, to identify outcome predictors, to assess quality of life, function, and costs (direct and indirect costs). CESPIC has been recently expanded to recruit patients with other forms of SpA / conditions associated with SpA: reactive arthritis, acute anterior uveitis, Crohn's disease as well as with psoriasis / axial psoriatic arthritis.

NCT ID: NCT05915676 Not yet recruiting - Autoimmune Diseases Clinical Trials

Role of LILRA3 in Ankylosing Spondylitis and Axial Psoriatic Patients

Start date: July 1, 2023
Phase:
Study type: Observational

1. To evaluate the frequency of LILRA3 in Ankylosing spondylitis and Axial psoriatic arthritis patients. 2. To investigate the association of LILRA3 with Ankylosing spondylitis and Axial psoriatic arthritis disease activity and severity.

NCT ID: NCT05760105 Not yet recruiting - Osteoporosis Clinical Trials

Awareness of Osteoporosis in Ankylosing Spondylosis Patients

Start date: December 1, 2023
Phase:
Study type: Observational [Patient Registry]

Osteoporosis is a condition that describes compromised skeletal microarchitecture in general, with clinical signs of decreased bone mineral density. Ankylosing spondylitis patients are at increased risk for developing osteoporosis. Identifying whether multiple sclerosis patients have information and awareness about this disease is crucial. This study is aimed to investigate awareness and knowledge of osteoporosis in ankylosing spondylitis patients.

NCT ID: NCT05703932 Not yet recruiting - Clinical trials for Ankylosing Spondylitis

Effect of Exercise on Disease Activity in Patients With Ankylosing Spondylitis by SIRI and SII

Start date: February 1, 2023
Phase: N/A
Study type: Interventional

The systemic inflammatory response index (SIRI) is defined as "neutrophil count × monocytes/lymphocyte counts". It has been reported that SIRI can predict survival in various types of cancer, including pancreatic cancer , gallbladder cancer , oral squamous cell carcinoma , and cervical cancer. Again, SIRI can demonstrate disease activity in patients with rheumatoid arthritis (RA), It has been reported that it can predict the development of RA-related interstitial lung disease and tumor development . Ankylosing spondylitis management strategies should be aimed at controlling disease activity, improving spinal mobility and functional status . Treatment usually includes the use of anti-inflammatory drugs to reduce pain and stiffness, and the use of disease-modifying drugs to try to stop or prevent disease progression. Patients are also advised to exercise to maintain the mobility of the spine and peripheral joints . Studies on this subject reveal that exercise is as important as drug therapy in the treatment of AS . Again, the importance of exercise in AS was emphasized in the clinical guidelines for the treatment of AS by ASAS (The Assesment in Ankylosing Spondylitis : Working Group) and EULAR (European League Against Rheumatism) . In addition to the effects of exercise on muscle strength, joint limitations, physical performance, endurance capacity and quality of life, its anti-inflammatory effects are also known. In this study, it was aimed to evaluate the effect of exercise therapy on disease activity in AS patients with systemic inflammatory response index (SIRI) and systemic inflammation index (SII). There is not enough evidence in the literature that systemic inflammatory response index (SIRI) and systemic inflammation index (SII) can be used in the evaluation of disease activity in AS.

NCT ID: NCT05190484 Not yet recruiting - Clinical trials for Rheumatoid Arthritis

bIosimilar of aDalimumab, an European evAluation

IDEA
Start date: April 30, 2022
Phase:
Study type: Observational

The study objective is aimed to describe all country, site, investigator and patient variables that lead to treatment persistence for at least 12 months among patients with rheumatologic and intestinal chronic inflammatory diseases who were switched to FK adalimumab, in order to develop a model to predict persistence at 12 months.

NCT ID: NCT05164198 Not yet recruiting - Clinical trials for Ankylosing Spondylitis

REduCed Dose of TNFi in Patients With Ankylosing SpondyliTis (RECAST)

Start date: January 15, 2022
Phase: Phase 4
Study type: Interventional

Participants maintaining stable disease activity of Ankylosing Spondylitis (AS) with standard-dose tumor necrosis factor inhibitor (TNFi) treatment will randomly split into two groups: maintaining standard-dose TNFi, versus reduced-dose TNFi. The proportion of participants not underwent flare between the two groups will be analyzed.